# Dosimetry

Source: https://nuclide.cc/terms/dosimetry/  
Nuclide record `dosimetry` (Term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Measuring how much radiation dose each organ and tumour actually received from a radioactive drug.

## Summary

Dosimetry is the measurement of how much radiation dose each organ and each tumour actually received from a radioactive drug. It relies on post-therapy SPECT/CT imaging at several time points and enables personalised activity prescription instead of fixed doses, and regulators and payers increasingly require it. The term is linked to the SPECT & bone scan and Radioligand therapy (beta emitters) technologies and to Radioembolisation (TARE / SIRT, yttrium-90), Auger-electron therapy and Total-body PET for screening. It is referenced by the Hepatocellular carcinoma and Neuroendocrine tumours entries, the radiopharmaceutical roadmap and the bottleneck on wrong doses, and by ideas on dosimetry-personalised PRRT instead of four fixed cycles and total-body PET for personalised radioligand dosing.

## Fields

- Kind: Term
- Last checked: 2026-09-04

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Dosimetry
- Wikipedia: https://en.wikipedia.org/wiki/Dosimetry

## Connected records

- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- technologies: [Alpha-emitter nanogenerators and daughter trapping](https://nuclide.cc/technologies/alpha-nanogenerators/), [Auger-electron therapy](https://nuclide.cc/technologies/auger-electron-therapy/), [Radioembolisation (TARE / SIRT, yttrium-90)](https://nuclide.cc/technologies/radioembolisation-tare/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [SPECT & bone scan](https://nuclide.cc/technologies/spect/), [Total-body PET for screening and ultra-low-dose imaging](https://nuclide.cc/technologies/total-body-pet-screening/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/)
- institutions: [European Association of Nuclear Medicine](https://nuclide.cc/institutions/eanm/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://nuclide.cc/institutions/inselspital-bern/), [International Atomic Energy Agency: Rays of Hope](https://nuclide.cc/institutions/iaea/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://nuclide.cc/institutions/irst-meldola/), [Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research](https://nuclide.cc/institutions/sahlgrenska/), [Society of Nuclear Medicine and Molecular Imaging](https://nuclide.cc/institutions/snmmi/)
- terms: [Gray unit (Gy)](https://nuclide.cc/terms/gray-unit/), [Half-life](https://nuclide.cc/terms/half-life/), [Pharmacokinetics (PK), half-life and exposure](https://nuclide.cc/terms/pharmacokinetics/), [PRRT (peptide receptor radionuclide therapy)](https://nuclide.cc/terms/prrt-term/)
- roadmaps: [Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose](https://nuclide.cc/roadmaps/dosimetry-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/)
- ideas: [Alpha-emitting PSMA therapy at first metastatic diagnosis](https://nuclide.cc/ideas/idea-alpha-first-mhspc/), [Dosimetry-personalised PRRT instead of four fixed cycles](https://nuclide.cc/ideas/idea-net-dosimetry-prrt/), [Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit](https://nuclide.cc/ideas/idea-reg-ac225-accelerator-pharmacopoeia/), [Total-body PET for personalised radioligand dosing](https://nuclide.cc/ideas/idea-total-body-pet-dosimetry/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/), [Wrong doses](https://nuclide.cc/bottlenecks/b-dose-optimisation/)
- key papers: [EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands](https://nuclide.cc/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/), [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- collections: [ICRP publications and dose coefficient databases](https://nuclide.cc/collections/icrp-publications/), [OpenDose](https://nuclide.cc/collections/opendose/)
- fronts: [Dosimetry](https://nuclide.cc/fronts/f-dosimetry/)

---
JSON: https://nuclide.cc/api/v1/entities/dosimetry.json